Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929454 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRHPGDHRH3KCNH2 | |
| SCHEMBL2929457 | 1.00 | ALDH1A1 (0.52) | ALDH1A1TSHRHPGDHRH3KCNH2 | |
| SCHEMBL12426677 | 0.93 | ALDH1A1 (0.59) | ALDH1A1TSHRHPGDHRH3KCNH2 | |
| SCHEMBL12632677 | 0.87 | ALDH1A1 (0.69) | ALDH1A1TSHRHPGDHRH3KCNH2 | |
| SCHEMBL17665942 | 0.87 | ALDH1A1 (0.69) | ALDH1A1TSHRHPGDHRH3KCNH2 | |
| SCHEMBL28782606 | 0.86 | ALDH1A1 (0.52) | ALDH1A1TSHRHPGDHRH3KCNH2 | |
| SCHEMBL2403345 | 0.84 | HRH3 (0.50) | ALDH1A1TSHRHPGDHRH3KCNH2 | |
| SCHEMBL2403351 | 0.84 | HRH3 (0.50) | ALDH1A1TSHRHPGDHRH3KCNH2 | |
| SCHEMBL2913936 | 0.84 | HRH3 (0.50) | ALDH1A1TSHRHPGDHRH3KCNH2 | |
| SCHEMBL1507352 | 0.81 | HRH3 (0.54) | ALDH1A1TSHRHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158189-B1 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| EP-2158189-B1 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544683-B2 | Cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-09 | — | — | US | disclosed |
| WO-2008151957-A9 | CYCLOHEXYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-03-05 | — | — | WO | disclosed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | disclosed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | disclosed |
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-01 | — | — | US | disclosed |
| WO-2008151957-A1 | CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005380-A1 | CYCLOHEXYL DERIVATIVES | HRH3, HRH4, HCAR2 | ALDH1A1 344/4885TSHR 119/4885HPGD 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.